Trifecta Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Trifecta Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4	Closed	-$1.34K	–	409
2024 Q3	$1.34K	Hold	4	–	–	﹤0.01%	350
2024 Q2	$1.09K	Buy	4 +2	+100%	+$582	﹤0.01%	371
2024 Q1	$692	Sell	2 -12	-86%	-$3.95K	﹤0.01%	398
2023 Q4	$4.52K	Buy	+14	New	+$4.39K	﹤0.01%	258
2023 Q2	–	Sell	-2	Closed	-$959	–	419
2023 Q1	$959	Hold	2	–	–	﹤0.01%	372
2022 Q4	$841	Buy	+2	New	+$807	﹤0.01%	386

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Trifecta Capital Advisors's BIO Position: Q4 2024 in Review

Trifecta Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2024, closing a stake of 4 shares — an estimated $1.34K sold.

Trifecta Capital Advisors first reported a position in BIO in Q4 2022 and held it in 6 quarters. The position peaked at $4.52K in Q4 2023. 456 funds tracked by Wall St. Rank hold BIO as of Q4 2024.

Trifecta Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q4 2024 after selling out during the quarter.
Trifecta Capital Advisors sold 4 Bio-Rad Laboratories Class A shares in Q4 2024, an estimated $1.34K.
Trifecta Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and held it in 6 quarters.
Trifecta Capital Advisors's Bio-Rad Laboratories Class A position peaked at $4.52K in Q4 2023.
456 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2024.

Based on Trifecta Capital Advisors's 13F filing for Q4 2024, filed 4 Feb 2025.